Program
TL-925
A development code.
Its studies are mostly in Conjunctivitis, Allergic · Dry Eye Syndromes, led by Telios Pharma.
Furthest: phase 2, since Feb 7, 20237 company-led studies, 5 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Telios Pharma | 75 open or running | phase 2since Feb 7, 2023 | Feb 7, 2023 | Mar 2027phase 2 · NCT07938632 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 7, 2023First study: phase 2 study in Dry Eye SyndromesFirst studyNCT05745064 · 107 enrolled · United States
- Oct 10, 2023Phase 2 study in Conjunctivitis, AllergicNCT06153342 · 70 planned · United States
- Jan 17, 2024Phase 2 study in Dry Eye SyndromesNCT06225973 · 880 enrolled · United States
- Feb 27, 2024Phase 2 study in Conjunctivitis, AllergicNCT06293820 · 80 enrolled · United States
- Nov 11, 2024Phase 2 study in Conjunctivitis, AllergicNCT06686472 · 66 planned · United States
- Oct 21, 2025Phase 2 study in Conjunctivitis, AllergicNCT07220408 · 60 planned · United States
- Nov 6, 2026Phase 2 study in Allergic Conjunctivitis of Both EyesNCT07938632 · 100 planned · United States
Ahead
- Mar 2027Primary completion: phase 2 study in Allergic Conjunctivitis of Both EyesNCT07938632
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07938632Allergic Conjunctivitis of Both Eyes · United States | 2 | Not yet recruiting | Mar 2027 | 100 |
| NCT07220408Conjunctivitis, Allergic · United States | 2 | Recruiting | Feb 2026 | 60 |
| NCT06686472Conjunctivitis, Allergic · United States | 2 | Recruiting | Dec 10, 2024 | 66 |
| NCT06293820Conjunctivitis, Allergic · United States | 2 | Completed | May 21, 2024 | 80 |
| NCT06225973Dry Eye Syndromes · United States | 2 | Active, not recruiting | Dec 2024 | 880 |
| NCT06153342Conjunctivitis, Allergic · United States | 2 | Recruiting | Jan 2024 | 70 |
| NCT05745064Dry Eye Syndromes · United States | 2 | Completed | Jul 11, 2023 | 107 |
How it is read
Names in the registry
- “TL-925”, 7 entries
Codes read as this program: TL925.
Conditions, from the studies’ own filings
- Conjunctivitis, Allergic, 5 studies
- Dry Eye Syndromes, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.